{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7TybMKDA","lastupdate":"2024-05-10T00:00:00.000Z","update_date":"2024-05-10T00:00:00.000Z","lastModified":"May 10, 2024","active":1,"confidence_score":92,"confidence_score_reason":"markets, not claimed","urlname":"notal-vision","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$4lwijJJP2CPUcvZHwNhhh6LK541guVEoxzuGxYqaTWBbcGfHhlXTRu","name":"Notal Vision","oneliner":"Remote Patient Monitoring for Retinal Diseases","registrar":"512995283","website":"http://www.notalvision.com","careerspage":"http://www.notalvision.com/careers","founded_month":8,"founded_year":2000,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/NotalVision","youtube":"https://www.youtube.com/channel/UCE_LNr1jOStRfPY_DH7ATZg","facebook":"","linkedin":"https://www.linkedin.com/company/52831","instagram":""},"social":["https://apps.apple.com/us/app/foreseehome-patient/id1373717769","https://twitter.com/NotalVision","https://www.linkedin.com/company/52831","https://www.youtube.com/channel/UCE_LNr1jOStRfPY_DH7ATZg"],"flattenedsociallinks":"https://apps.apple.com/us/app/foreseehome-patient/id1373717769|https://twitter.com/NotalVision|https://www.linkedin.com/company/52831|https://www.youtube.com/channel/UCE_LNr1jOStRfPY_DH7ATZg","apps":{"appstore":"https://apps.apple.com/us/app/foreseehome-patient/id1373717769","googleplay":""},"is_claimed_by_owner":1,"employees":"51-200","employees_exact":86,"patent":1,"raised":94050000,"stage":"D","public_stage":"D","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Notal Vision has developed a cloud-based platform designed to effectively and efficiently address large unmet diagnostic, economic, and social needs in the area of ophthalmology.\nThe company's integrated platform uses AI algorithms to detect and provide diagnostic decision support, driving at-home testing and patient-activated treatment. Using a monthly recurring subscription service model, the platform provides the basis for cost-effective solutions that can enhance both compliance and outcomes.\n\nNotal's ForeseeHome is an FDA-approved home monitoring test that supports earlier detection of wet age-related macular degeneration (AMD) in people with intermediate dry AMD. It is available only by physician order and covered by US Medicare.\n\nNotal also develops a home optical coherence tomography (OCT) solutions, noninvasive imaging technology for viewing retinal anatomy and assessing the need for treatment of age-related eye diseases that lead to blindness. In December 2018, Notal's Home OCT was granted Breakthrough status by the FDA and selected to participate in the FDA's OCT Innovation Pilot program.\n\nNotal's OCT Analyzer is a computational image analysis algorithm designed to provide automated detection of fluid in exudative retinal diseases.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"0522697768","country":null,"address":{"israeli":[{"id":"be8952ad-adb3-4b9b-b661-3c75ff95ec76","city":"Tel Aviv-Yafo","type":null,"address":"Druyanov Street 5, Tel Aviv-Yafo, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"b8ad8f88-a64b-4904-87bb-b8db737e2ea6","city":"Manassas","address":"7717 Coppermine Drive, Manassas, VA, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"mFtOd6kXxsoEneHuSjGLank6cna9ZzRRDRmTuqAflAhHE1DAe17EWk","date":"Mar 9, 2024","link":"https://www.ice.co.il/digital-140/news/article/1004117?_atscid=7_134353_204082920_2548794_0_Txtetaxjxdshwhus8sp","source":"www.ice.co.il","visible":1,"analysis":{"tags":"Healthcare, Technology","company":"NOTAL VISION","layoffs":"N/A","summary":"Israeli start-up NOTAL VISION, which provides patient-focused digital health services for remote monitoring, has won the Roche for a Better Future program. The companys technology expands the monitoring of retinal diseases from the clinic to the home, providing ophthalmologists with remote diagnostic tools to support their patients treatment. The technology allows for self-monitoring and home diagnosis, data analysis using artificial intelligence, and a customer support system. The company will begin clinical research at Beilinson Hospital with the support of Roche Israel.","partners":"Roche Israel, Beilinson Hospital","customers":"Patients with retinal diseases","investors":"Roche Israel","confidence":9,"key_topics":["Artificial Intelligence","Eye Health","Remote Monitoring","Clinical Research","Patient Care"],"date_of_event":"2024-11-03","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Partners, Investment","acquisition_amount":"N/A","structuredIssuesShow":"#Partners, Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4wEuROAhYzY5V1VxKgs6RR9cKyB5JjWJIEeGAlD3lJNG0jmwoi2N8s","news_summary":"בינה מלאכותית בשירות רפואת העיניים: \"פתרונות טכנולוגיים ברמה עולמית\"","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d9HXhiMQsTQckgNnKV5YnguUuurKnDhU7NjwLh574xpo8C1nPYwzlr","date":"Oct 8, 2023","link":"https://www.israel21c.org/new-technologies-to-help-us-see-better/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"Healthcare, Technology","company":"OrCam Technologies, CorNeat Vision, Notal Vision, Samsara Vision, AEYE, EyeYon Medical, NovaSight, EyeCan, DeepOptics, TopoSpeech, Orasis Pharmaceuticals","layoffs":"Not mentioned","summary":"The article discusses various Israeli companies that are developing innovative solutions to improve visual health. OrCam Technologies offers AI-driven reading aids for people with blindness or low vision. CorNeat Vision has developed a non-degradable tissue-integrating material technology for corneally blind people and those suffering from glaucoma. Notal Vision provides remote monitoring services for vision testing. Samsara Vision has developed an Implantable Miniature Telescope (IMT) for individuals with advanced, irreversible AMD. AEYE has developed a desktop system for diagnosing diabetic retinopathy. EyeYon Medical has developed cornea-focused sight-saving solutions. NovaSight offers eye-tracking-based solutions for early vision disorders. EyeCan is developing a smart headband for visually impaired swimmers. DeepOptics is developing personalized, connected glasses that dynamically correct vision impairment. TopoSpeech is developing a sensory substitution device for spatial information. Orasis Pharmaceuticals is developing corrective eye drops for treating presbyopia.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"Visual Impairment, Assistive Technology, AI, Medical Devices, Eye Health","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Notal Vision has raised over $100 million and is seeking an additional $20 million. EyeYon Medical raised a $26 million Series C round.","structured_issues":"Customers, Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers, Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"upg5HFtsbS5kwzH0s5pBPujrQhWDCHDcZW87eeWXiEvPnp3Gt3FxuX","news_summary":"11 promising new technologies to help us see better - ISRAEL21c","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Hrm5jClnymBTNlH92YrdBM0EGzFszGxTN16BXQ5AH0ONVeinfWkDgo","date":"Mar 7, 2022","link":"https://www.globenewswire.com/en/news-release/2022/03/08/2399097/0/en/Notal-Vision-Reports-Publication-of-First-U-S-Home-OCT-Study-Results.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Healthcare Technology","company":"Notal Vision","layoffs":"Not mentioned","summary":"Notal Vision, a digital healthcare provider, has announced the results of the first U.S.-based study with its investigational home-based optical coherence tomography (OCT) platform. The study found over 95% agreement when comparing retinal fluid detection capability, a primary marker for treatment guidance, between Notal Home OCT and in-office OCT. The results are significant for the management of patients suffering from wet age-related macular degeneration (AMD), the leading cause of blindness in the United States. The study also demonstrated the ease of use and convenience of daily imaging with the Notal Home OCT device.","partners":["Ophthalmic Consultants of Boston","Pepose Vision Institute"],"customers":"Patients with wet age-related macular degeneration","investors":["Genentech","Roche group"],"confidence":9,"key_topics":["Digital Healthcare","Ophthalmology","Artificial Intelligence","Remote Monitoring","FDA Clearance"],"date_of_event":"March 08, 2022","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aMuWKWGO4ChkWDNaj5TzEteh7v6EzG1YTsLQGH9HxGkUN5Aew2zPyn","news_summary":"Notal Vision Reports Publication of First U.S. Home OCT Study Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dd1585be-15aa-4528-9b50-21f0f40c6a90","date":"Jun 6, 2021","link":"https://en.globes.co.il/en/article-ophthalmic-monitoring-co-notal-vision-raises-60m-1001373422","source":"en.globes.co.il","visible":1,"analysis":{"tags":"investment","company":"Notal Vision","layoffs":null,"summary":"Notal Vision, an ophthalmic home monitoring services provider, has closed a Series D financing round of up to $60 million. The investment will support the commercial growth of the companys current service, the ForeseeHome AMD Monitoring Program, and the marketing strategy for its Home OCT pipeline technology. The funding will also allow Notal Vision to expand its remote patient monitoring services and build referral partnerships with ophthalmologists and optometrists. The company plans to introduce its Home OCT monitoring program for patients with exudative retinal diseases. Notal Vision is positioned to lead the ophthalmic home diagnostic services market and improve outcomes for patients with ocular diseases.","partners":null,"customers":null,"investors":["Soleus Capital","Ganot Capital","Elron Electronic Industries Ltd.","Evergreen"],"confidence":9,"key_topics":["Notal Vision","Series D financing","home monitoring services","ForeseeHome AMD Monitoring Program","Home OCT pipeline technology"],"date_of_event":"June 6, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$60 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yL5iMx977vQ3j0ph25p9urM0vu3dHVJo9sWPh1Uj1uuX4atPqVyWkI","news_summary":"Ophthalmic monitoring co Notal Vision raises $60m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fcf9e544-10f8-4470-96a9-a5d86efb97bb","date":"Apr 6, 2021","link":"https://www.globenewswire.com/en/news-release/2021/04/06/2204972/0/en/ForeseeHome-AMD-home-monitoring-real-world-data-analysis-demonstrates-substantial-benefit-for-patients-vision.html#:~:text=The%20large%20scale%20data%20analysis,outcomes%20of%20anti%2DVEGF%20treatment.","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"medical technology","company":"Notal Vision","layoffs":null,"summary":"Real-world data on the performance of Notal Visions ForeseeHome AMD Monitoring Program, a home-based diagnostic for age-related macular degeneration (AMD), was published in the Journal of Clinical Medicine. The data showed that the use of ForeseeHome provided a significant benefit to patients by helping to detect wet AMD earlier with better visual acuity. The studys principal author, Dr. Allen C. Ho, stated that earlier detection of wet AMD with this FDA-cleared device is a strong predictor of better vision outcomes. The ForeseeHome program, provided by Notal Vision, includes patient engagement, compliance monitoring, and alert generation services. The program resembles the findings of a randomized controlled study and has gained Medicare coverage. Notal Vision is a diagnostic services company that operates the Notal Vision Diagnostic Clinic.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["AMD Monitoring Program","Real-world data","Wet AMD","Visual acuity","Early detection"],"date_of_event":"2021-04-06","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JBFDjzizqvZphDtSELQuoYXTrZ5S68P3Eo4RstKFM3IjJnBIQkUhtJ","news_summary":"ForeseeHome AMD home monitoring real-world data analysis demonstrates substantial benefit for patients' vision","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"29209821-6df4-49ed-bf0b-df6026906b18","date":"Feb 23, 2021","link":"https://www.globenewswire.com/en/news-release/2021/02/23/2180426/0/en/AsclepiX-Therapeutics-partners-with-Notal-Vision-on-Home-OCT-remote-monitoring-in-DME-and-AMD-clinical-trials.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["data enrichment","patient-centric conduct","clinical trials"],"company":"Notal Vision","layoffs":null,"summary":"Notal Vision will provide AsclepiX Therapeutics with Home OCT monitoring services for their clinical trial program. The technology aims to enrich clinical trial datasets and reduce the burden of frequent office visits for patients with retinal diseases. The Home OCT device will be used by study subjects with diabetic macular edema and wet age-related macular degeneration to perform daily self-imaging of their eyes. The data will be transmitted to the Notal Health Cloud, where an AI-based analyzer will identify and quantify fluid in the eyes. The results will be shared with AsclepiX and the investigators. Notal Visions Home OCT technology has received FDA Breakthrough Device designation and is in the process of obtaining FDA clearance.","partners":["AsclepiX Therapeutics"],"customers":null,"investors":null,"confidence":8,"key_topics":["Home OCT monitoring","clinical trial program","diabetic macular edema","wet age-related macular degeneration","remote OCT monitoring"],"date_of_event":"February 23, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vSdit7XKxgtIXFsejCod3Tm3L5TB5OryDnLBs8AuA7lmiJxI8adgtR","news_summary":"AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f8b1f4dd-3d3f-43b0-97e6-3bc4d96e672b","date":"Aug 25, 2020","link":"https://www.globenewswire.com/news-release/2020/08/25/2083165/0/en/AI-based-OCT-analysis-of-AREDS2-10-Y-follow-on-study-demonstrates-superior-performance-over-retina-specialists.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Ophthalmology, OCT Analyzer","company":"Notal Vision","layoffs":null,"summary":"A study published in Ophthalmology shows that Notal Visions OCT Analyzer achieved a higher level of accuracy in detecting retinal fluid in wet age-related macular degeneration (AMD) compared to retina specialists. The study highlights the potential benefit of AI-assisted image review in routine clinical care. Notal Visions home-based OCT technology, which received FDA Breakthrough Device designation, aims to assist physicians in identifying, quantifying, and mapping intra- and subretinal fluid in wet AMD. The company is in the process of obtaining FDA clearance. Notal Visions Home OCT system allows wet AMD patients to perform technician-free OCT testing at home. The Notal OCT Analyzer (NOA) performs automated analysis of the Home OCT scans and generates a report for physicians when a change in disease activity is detected.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Ophthalmology","OCT Analyzer","Age-Related Eye Disease Study","machine learning","retinal fluid"],"date_of_event":"August 25, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CBCV0iFFqnuNqY6AePRloqkrEx9SnJO8hQX5GwGQVC9EfmZVHqB9xC","news_summary":"AI-based OCT analysis of AREDS2 10-Y follow-on study demonstrates superior performance over retina specialists","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"517bd344-a7db-4cb0-9eb5-71d98ba35874","date":"Aug 19, 2020","link":"https://www.businesswire.com/news/home/20200819005144/en/Notal-Vision-Diagnostic-Clinic-Implements-XIFIN-RPM-to-Improve-Claim-Accuracy-Timely-Reimbursement-and-Patient-Experience","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"2WMS3WQwi1mrewZec3U6hn0ya4sVo7ASAf1iN1ouLtIlbLEmEBPbba","news_summary":"Notal Vision Diagnostic Clinic Implements XIFIN RPM to Improve Claim Accuracy, Timely Reimbursement and Patient Experience","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"f380ee13-2e94-432e-a916-c3088e9dba12","date":"Feb 11, 2020","link":"https://www.globenewswire.com/news-release/2020/02/11/1982987/0/en/AI-based-retinal-fluid-analytics-of-serial-Notal-Vision-home-OCT-images-offers-insights-into-retinal-disease-dynamics.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["retinal imaging","home OCT","AMD","patient-operated device"],"company":"Notal Vision","layoffs":null,"summary":"Notal Vision presented longitudinal data on retinal imaging using their home OCT device at a medical meeting. The device, NOTAL-OCT V3.0, is designed to support the management of patients with age-related macular degeneration (AMD). The data showed that the device can track fluid in the retina over time and correlate it with disease status. The home OCT technology allows physicians to assess retreatment intervals and detect retinal fluid as soon as it occurs. Notal Visions home-based OCT pipeline technology has received FDA Breakthrough Device designation and is in the process of obtaining FDA clearance. The company aims to improve vision outcomes and reduce treatment burden through their diagnostic services and AI-enabled analyses of personalized health data.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["retinal imaging","home OCT","AMD","patient-operated device","data analysis"],"date_of_event":"2020-02-11","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oYdqK3oKoKdCAby8OwxU6ekIIL1Ac1pHyBgBoaeeUrC2CTIp0GvH1O","news_summary":"AI-based retinal fluid analytics of serial Notal Vision home OCT images offers insights into retinal disease dynamics","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"54979c7b-dfa6-46d5-8da9-b700d6467929","date":"Jan 8, 2020","link":"https://www.globenewswire.com/news-release/2020/01/08/1967788/0/en/CPT-codes-for-home-OCT-established.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["remote retinal optical coherence tomography","precision medicine","reimbursement","home-based OCT","physician and patient monitoring","clinical relevance","valuation","FDA Breakthrough Device designation","retinal disease management"],"company":"Notal Vision, Inc.","layoffs":null,"summary":"Notal Vision, Inc. announced that the American Medical Associations (AMA) CPT Editorial Panel has established three new Category III codes for patient-initiated remote retinal optical coherence tomography (OCT) scans using Notal Visions home-based OCT pipeline technology. The new codes allow for billing for device provision, set-up, patient education, technical support, data analyses, and reports. Notal Visions CEO believes that home-based OCT will be the future of monitoring patients with wet AMD. The companys next focus is proving clinical relevance and providing valuation to Medicare, Medicaid, and payors. Notal Visions home-based OCT pipeline technology received FDA Breakthrough Device designation in 2018 and has the potential to individualize and advance retinal disease management.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["CPT codes","home OCT pipeline technology","physician and patient reimbursement","clinical relevance","FDA Breakthrough Device designation"],"date_of_event":"January 8, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fmcyTi8TgZYRA7Jm6wdppqNbu1MPWOIwedVdGaRfyUDKEoN3m2pE4t","news_summary":"CPT codes for home OCT established","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6c630b21-55d5-451c-ba27-3fb3dbaa4957","date":"Dec 11, 2019","link":"https://techstartups.com/2019/12/11/israeli-healthtech-startup-notal-vision-secures-25m-provide-better-methods-detecting-age-related-macular-degeneration/","source":"techstartups.com","visible":1,"analysis":{"tags":"healthtech, funding","company":"Notal Vision","layoffs":null,"summary":"Notal Vision, a healthtech startup focused on advancing eye care, has raised $25 million in funding to support the growth of its current service and further research and development efforts. The funding was led by existing investor Ganot Capital. Notal Vision is developing a comprehensive diagnostic solution for the early detection and monitoring of Age-Related Macular Degeneration (AMD). The companys platform leverages AI-enabled analyses of personalized health data to improve vision outcomes. With the additional investment, Notal Vision aims to expand its sales team and drive deeper adoption of its home diagnostic services. The company is also well-funded to continue developing its Home OCT platform. Notal Vision is uniquely positioned to lead the ophthalmic home diagnostic services market.","partners":null,"customers":null,"investors":"Ganot Capital","confidence":9,"key_topics":["Notal Vision","Funding","ForeseeHome AMD Monitoring Program","AI-enabled analyses","Home OCT platform"],"date_of_event":"December 11, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$25 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1Zm7wbFKiHZ7zIyoryFggQKuNckH0FpfpmP5GePYFfwn9elQ1HaDct","news_summary":"Israeli healthtech startup Notal Vision secures $25M to provide better methods of detecting age-related macular degeneration","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4bf5b0d2-a0b3-42bf-96f9-c68912913204","date":"Oct 23, 2019","link":"http://www.globenewswire.com/news-release/2019/10/23/1934035/0/en/Notal-Vision-Announces-Appointment-of-Dr-Kester-Nahen-as-Chief-Executive-Officer.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"appointment","company":"Notal Vision","layoffs":null,"summary":"Notal Vision has appointed Kester Nahen as Chief Executive Officer to lead the companys next phase of growth. Nahen, who previously served as Chief Commercial Officer, brings extensive experience in the medical device industry. Notal Vision is focused on advancing eye care with precision medicine and extending disease management from the clinic to the home. The companys ForeseeHome and Home OCT diagnostic services programs aim to support patients throughout their journey from early diagnosis to personalized therapeutic management of retinal diseases. With Nahens leadership, Notal Vision aims to continue leading the ophthalmic home diagnostic services market through the development of low-cost medical devices, AI-driven decision support solutions, and a clinical patient engagement platform.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["appointment","growth","precision medicine","eye care","diagnostic services"],"date_of_event":"October 23, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MmVd2X2sZegVK8iW2zzGVglabvpzFm8FuvuwVARTHvT5zQikwLkS8M","news_summary":"Notal Vision Announces Appointment of Dr. Kester Nahen as Chief Executive Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9c4b313a-e497-482f-b518-ca7d96ec975b","date":"Jul 18, 2019","link":"https://www.globenewswire.com/news-release/2019/07/18/1884992/0/en/Notal-Vision-Diagnostic-Clinic-reports-completion-of-6-million-ForeseeHome-AMD-home-monitoring-tests.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Healthcare, Eye Care","company":"Notal Vision, Inc.","layoffs":"Not mentioned","summary":"Notal Vision, Inc., a company focused on eye care, has celebrated the completion of six million patient tests performed with ForeseeHome, the first FDA-cleared home-monitoring device for patients with intermediate dry Age-related Macular Degeneration (AMD) at risk for developing wet AMD. ForeseeHome uses a patented technology, Preferential Hyperacuity Perimetry® (PHP), that can identify minute changes in the central 14 degrees of visual field before the patient has any visual symptoms. The results are sent to the Notal Vision Diagnostic Clinic (NVDC) via a cloud-based ecosystem. If there is a significant change, the adaptive test will generate an alert which is provided to the patient’s eye doctor by the NVDC.","partners":"Not mentioned","customers":"Patients with intermediate dry Age-related Macular Degeneration","investors":"Not mentioned","confidence":9,"key_topics":["Eye Care","Home Monitoring","AMD","ForeseeHome","NVDC"],"date_of_event":"July 18, 2019","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Customers","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"OeXdoup5U3MjN6iQU6kJAoURczdIIOoV7cCwuEio3H3PBPDPud9P9T","news_summary":"Notal Vision Diagnostic Clinic reports completion of 6 million ForeseeHome AMD home-monitoring tests","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"772aed8c-b745-40bd-a784-4c06e67e3b89","date":"Dec 17, 2018","link":"https://www.prnewswire.com/news-releases/notal-vision-engages-wasatch-photonics-bringing-ai-enabled-home-based-optical-coherence-tomography-closer-to-market-300767431.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"ophthalmic diagnostic services","company":"Notal Vision, Inc.","layoffs":null,"summary":"Notal Vision has achieved a significant milestone in developing a home-based OCT system for monitoring exudative age-related macular degeneration (eAMD) patients. The system includes a patient-operated OCT device that generates images to be analyzed by an AI algorithm. The first U.S. clinical trial for the system began in October 2018. The images produced by the system have been deemed of excellent quality by retina specialists. The FDA has granted the system Breakthrough Device Designation. Notal Vision plans to expand its clinical trial program in 2019. Notal Vision leverages artificial intelligence and a cloud-based platform to connect healthcare providers, its Diagnostic Clinic, and patients for remote management of ophthalmic diseases.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["home-based OCT system","exudative age-related macular degeneration","clinical trial","artificial intelligence","cloud-based platform"],"date_of_event":"December 17, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zH9pN3tWoXLzhbmcNpeLN2H5M9EvB6FulMYkZ68qUTcLdMd2y8JXLL","news_summary":"Notal Vision Engages Wasatch Photonics Bringing AI-Enabled Home-Based Optical Coherence Tomography Closer to Market","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"18e1aa1a-dce3-4e90-b52e-be7998e2fbc8","date":"Dec 3, 2018","link":"https://www.prnewswire.com/news-releases/notal-vision-announces-fda-grants-breakthrough-device-designation-for-pioneering-patient-operated-home-optical-coherence-tomography-oct-system-300758956.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"FDA, Breakthrough Device, ophthalmic diagnostic services","company":"Notal Vision, Ltd.","layoffs":null,"summary":"Notal Vision, Ltd., a privately-held ophthalmic diagnostic services company, has received FDAs Breakthrough Device designation for its Home-based Optical Coherence Tomography (OCT) System. The system is an AI-based device for automated identification of intra- and/or subretinal fluid in eyes diagnosed with exudative age-related macular degeneration. The Notal Home OCT is a patient-friendly device that allows eAMD patients to perform OCT testing at home, with immediate notification to retinal specialists if recurrent disease activity is detected. Notal Vision plans to bring the Home OCT System to the market in 2020.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["FDA","Breakthrough Devices Program","Home OCT System","exudative age-related macular degeneration","cloud-based platform"],"date_of_event":"December 3, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GembDzKgeOa9MD0DXkWqIilhe3WUlcI9Z9VQ9ld7549IOmTLfgCvNJ","news_summary":"Notal Vision Announces FDA Grants Breakthrough Device Designation for Pioneering Patient-Operated Home Optical Coherence Tomography (OCT) System","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1ceba220-b84f-4e6b-8c00-40e17db99d3f","date":"Nov 8, 2017","link":"https://markets.businessinsider.com/news/stocks/notal-vision-to-present-on-home-based-optical-coherence-tomography-at-the-upcoming-ophthalmology-innovation-summit-in-new-orleans-1007295080","source":"markets.businessinsider.com","visible":1,"analysis":{"tags":"ophthalmic, remote diagnostic testing","company":"Notal Vision","layoffs":null,"summary":"Notal Vision, a privately-held ophthalmic company, will be presenting at the Ophthalmology Innovation Summit. They will be showcasing their Home OCT device in development, which is part of their cloud-based platform for remote diagnostic testing. The device aims to personalize wet AMD management and improve long-term visual acuity maintenance. Notal Vision has established a seamless, cloud-based platform that connects healthcare providers and patients for the detection of ocular diseases. The company was founded by two ophthalmologists and is focused on providing innovative, home-based diagnostic technologies for patients with retinal diseases.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Ophthalmology Innovation Summit","Home OCT device","retinal diseases","cloud-based platform","Notal OCT Analyzer"],"date_of_event":"November 9th, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iqAvSTt5oEnxGAFWZ0OQQDvBPxdkFcX1Fb7Kda5PC7PjbD64t0eN0F","news_summary":"Notal Vision to Present on Home-based Optical Coherence Tomography at the Upcoming Ophthalmology Innovation Summit in New Orleans","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f55576be-bdbd-43fa-8d5e-6e17546d211c","date":"Oct 11, 2017","link":"https://eyewire.news/articles/notal-vision-announces-study-collaboration-with-american-academy-of-ophthalmology-iris-registry-to-gain-insight-on-real-world-visual-acuity-in-amd/","source":"eyewire.news","visible":1,"analysis":{"tags":"N/A","company":"Eyewire+","layoffs":"N/A","summary":"The article provides information about Eyewire+ as a source for updates in the ophthalmic field.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":[],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"N/A","investment_amount":"N/A","structured_issues":[],"acquisition_amount":"N/A","entityGrowthIconPath":"none;"},"sentiment":"N/A","analysisId":"tk9ktFvxe5rlJTceBfrMD4Tm6JRyyFA4B4CGM0GaNI6IU8HIp4HI2a","news_summary":"News - Eyewire+","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d5e4da43-ce08-4bec-8ece-72152eb7fb04","date":"Oct 5, 2017","link":"https://www.bizjournals.com/washington/prnewswire/press_releases/Virginia/2017/10/05/FL07873","source":"www.bizjournals.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"HaZSZ4Vem6X4creQCb0ocSWC0FyE15X19uIkrLd2E75IpgjMwGIrp7","news_summary":"BizSpotlight Press Releases - Washington Business Journal","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"06ac9d60-3583-4a0d-82be-228b87408e6c","date":"Aug 2, 2017","link":"https://www.healio.com/optometry/business-of-optometry/news/online/%7Bbfbd7dd9-a597-4bab-8e28-f7842666895d%7D/notal-vision-announces-new-cio","source":"www.healio.com","visible":1,"analysis":{"tags":"appointment, cloud-based technology, capabilities","company":"Notal Vision Ltd.","layoffs":"","summary":"Notal Vision Ltd. has appointed Roni Amiel as chief information officer to advance the companys cloud-based technology and capabilities. The appointment is seen as a step forward in Notal Visions growth as a pioneer in home-based telemonitoring for ocular diseases. Notal Vision has a cloud-based infrastructure that connects healthcare providers and patients for personalized, home-based detection and monitoring of ocular diseases.","partners":"","customers":"","investors":"","confidence":9,"key_topics":["appointment","cloud-based technology","capabilities","home-based telemonitoring","ocular diseases"],"date_of_event":"August 02, 2017","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":["Management Changes"],"acquisition_amount":"","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2mAxr7qNFkRNsLiQv7vpP3mOPN9UYvX42zUhoYSnvna0nRSbLqS2x4","news_summary":"Notal Vision announces new CIO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8faae906-67db-4d59-8fe1-b13012418aba","date":"Jul 24, 2017","link":"https://www.prnewswire.com/news-releases/notal-vision-names-jim-long-as-chief-financial-officer-300492749.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"appointment","company":"Notal Vision","layoffs":null,"summary":"Notal Vision has appointed Jim Long as Chief Financial Officer. Long will be responsible for the companys financial operations and strategy. The appointment is expected to help Notal Vision meet its ambitious growth goals. Long has over 25 years of experience in private healthcare technology and services companies. Notal Vision is a privately-held ophthalmic company that developed ForeseeHome, the first FDA-cleared home-based monitoring system for patients with age-related macular degeneration (AMD). The company focuses on providing innovative, home-based technology solutions for visual health in AMD patients.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Chief Financial Officer","home-based monitoring system","age-related macular degeneration","financial operations and strategy","growth goals"],"date_of_event":"July 24, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2nMxIpEx333Rlu9fiKH96JkEkI1AUfbk06OXRobZQYI29sg4uvUROg","news_summary":"Notal Vision Names Jim Long as Chief Financial Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"70ce4f71-7bf7-48db-ac52-eb6e6d036860","date":"Feb 29, 2016","link":"https://www.businesswire.com/news/home/20160229005871/en/Notal-Vision-Achieves-Medicare-Coverage-ForeseeHome","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Product Launch, Healthcare","company":"Notal Vision, Inc.","layoffs":"N/A","summary":"Notal Vision, Inc. has announced that its ForeseeHome AMD Monitoring Program is now available for eligible Medicare patients across the U.S. The program is designed for patients with Dry Age-related Macular Degeneration (AMD) who are at high risk of developing Wet AMD. The ForeseeHome program was tested in a National Eye Institute-sponsored study, where it was found to significantly increase early detection of wet AMD. Notal Vision has been working for nearly two years to make this device available to Medicare patients.","partners":"N/A","customers":"Medicare patients","investors":"N/A","confidence":8,"key_topics":["ForeseeHome AMD Monitoring Program","Medicare","Dry Age-related Macular Degeneration","Telemonitoring technology","Ophthalmology"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Od8XtLWrwWEQVepBLBKzffxC1hr8CvC6q1b7IbFjpXUYbe4txURqtn","news_summary":"Notal Vision Achieves Medicare Coverage For ForeseeHome","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f361fe74-5969-432e-85c4-ba2a30bcac33","date":"May 4, 2003","link":"https://www.israel21c.org/notal-vision-sets-its-sights-on-early-detection-of-amd/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"medical technology","company":"Notal Vision","layoffs":null,"summary":"Notal Vision, an Israeli medical technology company, has developed a device called Macular Computerized Psychophysical Test (MCPT) that can detect age-related Macular Degeneration (AMD) more accurately and earlier than the current standard diagnostic. In clinical studies, the MCPT was shown to be more than twice as likely to detect the presence of AMD. The device uses hyperacuity to detect retinal lesions from AMD, allowing for early treatment initiation. Notal Vision has partnered with Carl Zeiss Meditec Inc. for worldwide distribution rights to the device. Sales of the device will begin in the summer.","partners":"Carl Zeiss Meditec Inc.","customers":null,"investors":null,"confidence":9,"key_topics":["AMD","Macular Degeneration","Diagnostic Test","Early Detection","Distribution Agreement"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"coXPP62ghXwiAUOtyqoYodha4yFYMyYGSDuEMpVKyUhoKBOKXdEaDf","news_summary":"Notal Vision sets its sights on early detection of AMD","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e218772a-e3af-47d1-9ee2-1a3b47c727d3","date":"Jan 27, 2003","link":"https://en.globes.co.il/en/article-657400","source":"en.globes.co.il","visible":1,"analysis":{"tags":"medical diagnostics","company":"Notal Vision","layoffs":null,"summary":"Notal Vision, a developer of medical diagnostic solutions, has successfully completed a $4 million financing round. The companys diagnostic solution is designed to detect age-related macular degeneration. Investors in the round included Elron, InnoMed Ventures, and a group of private investors. Notal Vision recently signed a distribution agreement with Carl Zeiss Meditec. The funding will enable the company to start shipping products and develop future products. Notal Vision aims to become the gold standard in AMD detection and monitoring.","partners":"Carl Zeiss Meditec","customers":null,"investors":"Elron, InnoMed Ventures, private investors","confidence":9,"key_topics":["Diagnostic solution","Financing round","Investors","Distribution agreement","Age-related macular degeneration"],"date_of_event":"2003-01-27","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$4 million","structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZkGfQD2ZBROhwxmUanlBlREgzUIgmoadVovZu4IrkuvK1GZTwhsdEI","news_summary":"Notal Vision raises $4m from Elron and Innomed","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":23,"techcommunityinvolvement":null,"mediagallery":[{"id":"oxnw4sh2nl2kY4ssxbVuqxVDYKUqweg00Du0f77ZF0cdAKnds5iNBS","timestamp":"2024-05-10 12:56:47.000000","resources_type":2,"resources_title":"","resources_file_name":"2lJaOG_InYo","alt":"","imageurl":"https://img.youtube.com/vi/2lJaOG_InYo/0.jpg","url":"http://youtu.be/2lJaOG_InYo"},{"id":"f7671e61-fd41-40f7-adae-7e1c2cf8c27b","timestamp":"2020-02-19 11:37:16.000000","resources_type":2,"resources_title":"What is AMD?","resources_file_name":"zy55g3v4mYc","alt":"What is AMD? logo","imageurl":"https://img.youtube.com/vi/zy55g3v4mYc/0.jpg","url":"http://youtu.be/zy55g3v4mYc"},{"id":"f477dbb6-79cc-49eb-bf62-f9c387950690","timestamp":"2020-02-19 11:36:56.000000","resources_type":2,"resources_title":"What is ForeseeHome?","resources_file_name":"1stn5PkN5U8","alt":"What is ForeseeHome? logo","imageurl":"https://img.youtube.com/vi/1stn5PkN5U8/0.jpg","url":"http://youtu.be/1stn5PkN5U8"},{"id":"07de7c11-4be7-45b9-a88e-491ef40a445e","timestamp":"2020-02-19 11:36:32.000000","resources_type":2,"resources_title":"ForeseeHome Patient Testimonial","resources_file_name":"bG6n9VRe8Tk","alt":"ForeseeHome Patient Testimonial logo","imageurl":"https://img.youtube.com/vi/bG6n9VRe8Tk/0.jpg","url":"http://youtu.be/bG6n9VRe8Tk"}],"tags":["telemedicine","degenerative-diseases","digital-healthcare","home-care","diagnostics","prevention","early-detection","ophthalmology","medical-devices","monitoring","cloud-based","detection","artificial-intelligence","adherence","telehealth","aging-population","decision-making","data-analytics","seniors","eye-diseases","doctors","imaging","non-invasive"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B2C"],"productstage":"Released","products":["Notal OCT Analyzer (NOA)","ForeseeHome","Optical coherence tomography (OCT)"],"geomarkets":["United States","Israel"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":6,"lastfunding":"$60M","totalrounds":6,"fundingstage":"D","totalfunding":"$94.05M","publicinvestors":6,"lastpublicfunding":60000000,"totalpublicrounds":6,"totalpublicfunding":94050000},"team":[{"name":"Kester Nahen, , PHD","email":"knahen@notalvision.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4ObKt_EIDA","bounced":true,"claimed":0,"founder":0,"urlname":"kester-nahen-phd","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDglvWdgwsM","position":"CEO","last_name":"Nahen, , PHD","claimtoken":"vmaWkYbFHf3vRodFsy8sA84VWJU2WpUvAeY1biq9lB5IIXpmr9mbL9","first_name":"Kester","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/kester-nahen-phd-ba6a178/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-05-10 12:50:25.000000","initials":"KN","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Gibb Clarke","email":"","phone":"","gender":"Male","userid":"CbuBsEshjvMdpJhDFe8xPLX0WJdhMAMjHUREAswMYcN9LgCpKDqZo5","bounced":false,"claimed":null,"founder":0,"urlname":"gibb-clarke","visible":1,"memberid":"ZYByMVixbDc7jmkAz9wiwSe2jSl7VGaAkFEs8LlevsTIynQYwhbdNR","position":"CFO","last_name":"Clarke","claimtoken":null,"first_name":"Gibb","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"GC","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Gidi  Benyamini","email":"gidibenyamini@gmail.com","phone":"","gender":"Male","userid":"PKPVfzV89dHxcSL49xMBLRTnCuWcEFRiDtQE0AEtVGg2PID9wlrvNX","bounced":false,"claimed":1,"founder":0,"urlname":"gidi-benyamini","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAvo6niggM","position":"CTO & Director of Notal Vision Innovation Center","last_name":"Benyamini","claimtoken":"UR9aND1mZDSFYgIMsCHh06Uho11jylljHKqV1JQkdwhVcVyWxnXaxU","first_name":"Gidi ","picturekey":null,"claimeddate":"2023-10-01","linkedinurl":"https://www.linkedin.com/in/gidi-benyamini-12b0a822/","unsubscribed":false,"is_activeuser":1,"additionalemail":"gBenyamini@notalvision.com","claimedemaildate":"2023-09-28 14:44:59.000000","initials":"GB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Muki Rapp, PHD","email":"mrapp@notalvision.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NakwOoJDA","bounced":false,"claimed":0,"founder":0,"urlname":"muki-rapp-phd","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg5rjuoAoM","position":"Executive VP R&D","last_name":"Rapp, PHD","claimtoken":"xqwNV1s4Fvgo64mMmd1I7FFsClgnY7rGBnShJWOP25jKVxyh9h0AKP","first_name":"Muki","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/muki-rapp-06504818/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-05-10 12:50:29.000000","initials":"MR","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Barbara Benedict","email":"bbenedict@notalvision.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Oa47qAJDA","bounced":false,"claimed":0,"founder":0,"urlname":"barbara-benedict","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgpuuf5QkM","position":"VP Diagnostic Clinic Strategy & Operations","last_name":"Benedict","claimtoken":"EBAATsDBDGk15bnSX1Ux7YMEB66FfV8aDjVzvq5G1ISo0hwso8lTFJ","first_name":"Barbara","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/barbara-benedict-82641111/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-05-10 12:50:36.000000","initials":"BB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Nishant Mohan","email":"","phone":"","gender":"Male","userid":"S2hzU2iqJ9MODvLTZhUUehgQWztp3l7vGqgmGZcECtFpwWj6kVdfTV","bounced":false,"claimed":null,"founder":0,"urlname":"nishant-mohan","visible":1,"memberid":"Mjux2vrltE8MtAsMBXf5woUof6RmIKeq8FJWG1J83saLZsNEuQwgp3","position":"VO Product","last_name":"Mohan","claimtoken":null,"first_name":"Nishant","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"NM","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwPi8kYoKDA","fullname":"Ayelet Beazley"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2020-02-19T00:00:00.000Z","crunchbaseid":"notal-vision","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Tamar Weiss","creator_email":"tamar.e.weiss@gmail.com","createdate":"2014-07-31T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":"Ayelet Beazley","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD3zu2ICgw","date":"Jun 2021","amount":"$60M","source":"https://en.globes.co.il/en/article-ophthalmic-monitoring-co-notal-vision-raises-60m-1001373422","eventtype":"FundingRoundEvent","investment":[{"name":"Elron Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/elron-electronic-industries","logokey":"$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","tagline":null,"urlname":"/investor_page/elron-electronic-industries","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwL3Fr5IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4e158265-d079-4ce6-8b8c-8faaa7fa967a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Evergreen Venture Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/evergreen-venture-partners","logokey":"$6flu5zJvRxUjkz2CbukfNlMqHFy67Pk4uQJkV1SaQAgPquyHQNx46r","tagline":null,"urlname":"/investor_page/evergreen-venture-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMm81pMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5f453dd5-d176-4225-a31c-04db7e2aced5","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6flu5zJvRxUjkz2CbukfNlMqHFy67Pk4uQJkV1SaQAgPquyHQNx46r","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Soleus Capital ","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/soleus-capital","logokey":"$Ck85IdWZZH9MEwMvOclhEFYOOv0vtrIRrCZGNXvMqBWwIVEw5MeK1P","tagline":"","urlname":"/investor_page/soleus-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCP-MCwCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"a934fac3-c0b2-4bc4-ae5e-7c9c6be2bd88","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Ck85IdWZZH9MEwMvOclhEFYOOv0vtrIRrCZGNXvMqBWwIVEw5MeK1P","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"D Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":60000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD6hO_7CAw","date":"Dec 2019","amount":"$25M","source":"https://techstartups.com/2019/12/11/israeli-healthtech-startup-notal-vision-secures-25m-provide-better-methods-detecting-age-related-macular-degeneration/, https://www.globenewswire.com/news-release/2019/12/11/1959167/0/en/Notal-Vision-secures-25-million-in-recent-funding-round-for-ForeseeHome-and-pipeline-technologies.html","eventtype":"FundingRoundEvent","investment":[{"name":"Ganot Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/ganot-capital-1","logokey":"$bKzFT4Pt9e3h9SwkxvdT0f2NQbZOCXbefBLJwcoFrn5AJKgg2VHWfU","tagline":"","urlname":"/investor_page/ganot-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODaiYrKCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"91739096-5e47-497d-88e0-479bb71f75f6","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$bKzFT4Pt9e3h9SwkxvdT0f2NQbZOCXbefBLJwcoFrn5AJKgg2VHWfU","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":25000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD42eOvCww","date":"May 2013","amount":"$50K","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Arch Grants","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/arch-grants","logokey":"$ZKl39qt410ALpk65LvgyHugzMFlh5ksLC1kfUOleTl2lp5Hu3z32Bp","tagline":"","urlname":"/company_page/arch-grants","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv6DeCAw","fundingtype":"Other","leadpartner":null,"investmentid":"7fefaa45-f455-4a6c-b3ca-f3298736bdc8","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZKl39qt410ALpk65LvgyHugzMFlh5ksLC1kfUOleTl2lp5Hu3z32Bp","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":50000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkjqrkCAw","date":"Jun 2012","amount":"$5M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Elron Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/elron-electronic-industries","logokey":"$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","tagline":null,"urlname":"/investor_page/elron-electronic-industries","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwL3Fr5IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c7509464-319e-4923-801f-16591c53d756","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2uXQCQw","date":"Jan 2003","amount":"$4M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Innomed Ventures","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/innomed-ventures-1","logokey":null,"tagline":"","urlname":"/investor_page/innomed-ventures-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwMmcCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"111f09ee-efe2-4b1e-aad2-f0b7a8c3f05b","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Elron Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/elron-electronic-industries","logokey":"$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","tagline":null,"urlname":"/investor_page/elron-electronic-industries","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwL3Fr5IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9e891b2b-f5ee-43ba-b1a3-89894a7be5c1","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":4000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODk2J6FCww","date":"May 2001","amount":"Undisclosed","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Jerusalem Global Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/jerusalem-global-ventures","logokey":"$1VUP8BPseU7qN2EKpc91PiH8NsjeA5PsRc8cAzGIv3DViJpUJ0jEt6","tagline":null,"urlname":"/investor_page/jerusalem-global-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwKTN_pEJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9dee9eef-2ed6-40d5-a1f0-addb9d490b44","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$1VUP8BPseU7qN2EKpc91PiH8NsjeA5PsRc8cAzGIv3DViJpUJ0jEt6","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"8/2000","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Notal Vision","logourl":"https://storage.googleapis.com/clean-finder-353810/$4lwijJJP2CPUcvZHwNhhh6LK541guVEoxzuGxYqaTWBbcGfHhlXTRu","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$4lwijJJP2CPUcvZHwNhhh6LK541guVEoxzuGxYqaTWBbcGfHhlXTRu","seoabout":"Notal Vision has developed a cloud-based platform designed to effectively and efficiently address large unmet diagnostic, economic, and social needs in the...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":6,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Medical Diagnostics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Data Storage","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","classificationName":"coretechnology"},{"depth":2,"name":"Cloud","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":1,"name":"Simulation & Imaging","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Seniors","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA>Seniors#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","TechnologyClassificationModel>Simulation & Imaging#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA>Digital Medical Diagnostics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","TechnologyClassificationModel>Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA>Cloud#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA|2:>TechnologyClassificationModel>Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA/Cloud#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|1:>TechnologyClassificationModel/Simulation & Imaging#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA|2:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA/Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA|3:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA/Seniors#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA/Digital Medical Diagnostics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Digital Healthcare","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare","children":[{"title":"Digital Medical Diagnostics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare>Digital Medical Diagnostics"}]}]}],"targetCustomer":[{"title":"Consumers","key":"0-0","path":"IndustryClassificationModel>Consumers","children":[{"title":"Demographics & Family","key":"0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family","children":[{"title":"Seniors","key":"0-0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family>Seniors"}]}]},{"title":"Healthcare & Life Sciences","key":"0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-1-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]}],"coreTechnology":[{"title":"Data Storage","key":"0-0","path":"TechnologyClassificationModel>Data Storage","children":[{"title":"Cloud","key":"0-0-0","path":"TechnologyClassificationModel>Data Storage>Cloud"}]},{"title":"Artificial Intelligence","key":"0-1","path":"TechnologyClassificationModel>Artificial Intelligence"},{"title":"Simulation & Imaging","key":"0-2","path":"TechnologyClassificationModel>Simulation & Imaging"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Medical Diagnostics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvnms8LDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Data Storage","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","classificationName":"coretechnology"},{"depth":2,"name":"Cloud","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":1,"name":"Simulation & Imaging","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lvn0O8LDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Seniors","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Digital Healthcare","Digital Medical Diagnostics"],"coreTechnology":["Data Storage","Cloud","Artificial Intelligence","Simulation & Imaging"],"targetCustomer":["Consumers","Demographics & Family","Seniors","Healthcare & Life Sciences","Healthcare","Providers"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD3zu2ICgw","date":"Jun 2021","amount":"$60M","source":"https://en.globes.co.il/en/article-ophthalmic-monitoring-co-notal-vision-raises-60m-1001373422","eventtype":"FundingRoundEvent","investment":[{"name":"Elron Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/elron-electronic-industries","logokey":"$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","tagline":null,"urlname":"/investor_page/elron-electronic-industries","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwL3Fr5IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4e158265-d079-4ce6-8b8c-8faaa7fa967a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Evergreen Venture Partners","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/evergreen-venture-partners","logokey":"$6flu5zJvRxUjkz2CbukfNlMqHFy67Pk4uQJkV1SaQAgPquyHQNx46r","tagline":null,"urlname":"/investor_page/evergreen-venture-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMm81pMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5f453dd5-d176-4225-a31c-04db7e2aced5","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$6flu5zJvRxUjkz2CbukfNlMqHFy67Pk4uQJkV1SaQAgPquyHQNx46r","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Soleus Capital ","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/soleus-capital","logokey":"$Ck85IdWZZH9MEwMvOclhEFYOOv0vtrIRrCZGNXvMqBWwIVEw5MeK1P","tagline":"","urlname":"/investor_page/soleus-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCP-MCwCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"a934fac3-c0b2-4bc4-ae5e-7c9c6be2bd88","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Ck85IdWZZH9MEwMvOclhEFYOOv0vtrIRrCZGNXvMqBWwIVEw5MeK1P","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"D Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":60000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD6hO_7CAw","date":"Dec 2019","amount":"$25M","source":"https://techstartups.com/2019/12/11/israeli-healthtech-startup-notal-vision-secures-25m-provide-better-methods-detecting-age-related-macular-degeneration/, https://www.globenewswire.com/news-release/2019/12/11/1959167/0/en/Notal-Vision-secures-25-million-in-recent-funding-round-for-ForeseeHome-and-pipeline-technologies.html","eventtype":"FundingRoundEvent","investment":[{"name":"Ganot Capital","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/ganot-capital-1","logokey":"$bKzFT4Pt9e3h9SwkxvdT0f2NQbZOCXbefBLJwcoFrn5AJKgg2VHWfU","tagline":"","urlname":"/investor_page/ganot-capital-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODaiYrKCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"91739096-5e47-497d-88e0-479bb71f75f6","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$bKzFT4Pt9e3h9SwkxvdT0f2NQbZOCXbefBLJwcoFrn5AJKgg2VHWfU","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":25000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkjqrkCAw","date":"Jun 2012","amount":"$5M","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Elron Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/elron-electronic-industries","logokey":"$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","tagline":null,"urlname":"/investor_page/elron-electronic-industries","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwL3Fr5IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c7509464-319e-4923-801f-16591c53d756","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2uXQCQw","date":"Jan 2003","amount":"$4M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Innomed Ventures","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/innomed-ventures-1","logokey":null,"tagline":"","urlname":"/investor_page/innomed-ventures-1","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODkwMmcCww","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"111f09ee-efe2-4b1e-aad2-f0b7a8c3f05b","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Elron Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/elron-electronic-industries","logokey":"$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","tagline":null,"urlname":"/investor_page/elron-electronic-industries","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwL3Fr5IKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9e891b2b-f5ee-43ba-b1a3-89894a7be5c1","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$naJ1vN6M8eWNchntkbbrpzn1WSB5Nii3m2JmuT19MrmD8XgLNOZSvS","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":4000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODk2J6FCww","date":"May 2001","amount":"Undisclosed","source":"","eventtype":"FundingRoundEvent","investment":[{"name":"Jerusalem Global Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/jerusalem-global-ventures","logokey":"$1VUP8BPseU7qN2EKpc91PiH8NsjeA5PsRc8cAzGIv3DViJpUJ0jEt6","tagline":null,"urlname":"/investor_page/jerusalem-global-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwKTN_pEJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9dee9eef-2ed6-40d5-a1f0-addb9d490b44","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$1VUP8BPseU7qN2EKpc91PiH8NsjeA5PsRc8cAzGIv3DViJpUJ0jEt6","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD42eOvCww","date":"May 2013","amount":"$50K","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Arch Grants","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/arch-grants","logokey":"$ZKl39qt410ALpk65LvgyHugzMFlh5ksLC1kfUOleTl2lp5Hu3z32Bp","tagline":"","urlname":"/company_page/arch-grants","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv6DeCAw","fundingtype":"Other","leadpartner":null,"investmentid":"7fefaa45-f455-4a6c-b3ca-f3298736bdc8","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZKl39qt410ALpk65LvgyHugzMFlh5ksLC1kfUOleTl2lp5Hu3z32Bp","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":50000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}